Raymond James raises Relay Therapeutics price target on trial data

Raymond James raised Relay Therapeutics’ price target to $23 from $19 while keeping a Strong Buy rating after new proof-of-concept data for zovegalisib combined with atirmociclib and fulvestrant in HR+/HER2- PIK3CAmut metastatic breast cancer. The firm said efficacy was in line with expectations and the safety profile looked favorable, supporting plans to advance the triplet into frontline pivotal development in early 2027. Relay shares trade at $14.98, up 373% over the past year but down 7.7% in the last week.

Analysis

RLAY is transitioning from a binary-data story to a platform-credibility story: the market is now underwriting a much higher probability that zovegalisib can become a durable backbone therapy rather than a niche monotherapy asset. The bigger implication is second-order competitive pressure on oral PI3K/AKT-pathway programs and on any late-stage entrant hoping to capture frontline HR+/HER2- PIK3CAmut share; once safety looks “good enough” in combination, differentiation shifts from efficacy novelty to convenience, tolerability, and sequencing speed.

The near-term setup is less about the readout itself and more about how quickly management can convert enthusiasm into trial design, partner interest, and valuation support. The stock has already repriced sharply over the past year, so incremental upside now depends on whether the new regimen meaningfully expands addressable duration-of-therapy assumptions, not just peak response rates. That creates a classic overhang: if follow-up data do not show cleaner efficacy at the eventual Phase 3 dose, the multiple can compress even if the program remains viable.

The contrarian risk is that investors may be extrapolating a frontline win too aggressively from later-line dose-escalation data. In this space, the real economic value is often captured by whoever controls the pivotal path, the combo partners, and the commercial sequencing—not necessarily the first mover with encouraging early data. If the triplet becomes crowded by competing mechanistic approaches or payer pushback on multi-drug regimens, the long-duration value case narrows materially over the next 12-24 months.

Key Decisions for Investors

• Long RLAY on pullbacks over the next 1-3 weeks; use a 10-12% stop from entry and target a 15-25% move into the next trial-design or follow-up catalyst.
• Sell downside puts in RLAY 3-6 months out if implied vol remains elevated; the thesis is that near-term downside is cushioned by renewed analyst support, while upside still depends on a slower fundamental re-rate.
• Pair trade: long RLAY / short a basket of late-stage oncology names with weaker combo/safety data; the trade expresses winner-take-more in pathway oncology while isolating general biotech beta.
• Take partial profits into any gap-up above prior highs; this is now a “show-me” name and momentum can fade quickly if follow-up data are not clearly superior.
• For event-driven accounts, consider a small-call-spread structure in RLAY 6-9 months out to capture the next readout window with defined risk and limited theta bleed.